Savara Inc Total Liabilities
Savara Inc total liabilities. Based on the latest financial reports, Savara Inc (SVRA) has total liabilities worth $48.48 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Savara Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Savara Inc (2000–2025)
Total liabilities of Savara Inc from 2000 to 2025. This chart illustrates how Savara Inc's total liabilities have evolved over time, based on quarterly financial data. Explore SVRA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Savara Inc Competitors by Total Liabilities
The table below lists competitors of Savara Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
USA | $1.88 Billion |
|
Wuxi Chipown Micro-electronics Ltd
SHG:688508
|
China | CN¥796.79 Million |
|
Ategrity Specialty Insurance Company Holdings
NYSE:ASIC
|
USA | $887.70 Million |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$167.95 Million |
|
Tianjin You Fa Steel Pipe Group Stock Co Ltd
SHG:601686
|
China | CN¥19.30 Billion |
|
Gracell Biotechnologies Inc.
NASDAQ:GRCL
|
USA | $268.86 Million |
|
Max Zipper Co Ltd
TWO:8932
|
Taiwan | NT$1.16 Billion |
|
Starlake Bioscience Co Inc Zhaoqing Guangdong
SHG:600866
|
China | CN¥8.99 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Savara Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SVRA total assets.
Liquidity & Leverage Metrics
Savara Inc Total Liabilities Ratios Explained
Savara Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Savara Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Savara Inc (2000–2025)
The table below shows the annual total liabilities of Savara Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.30 Million | +21.42% |
| 2024-12-31 | $41.43 Million | +11.39% |
| 2023-12-31 | $37.19 Million | +16.23% |
| 2022-12-31 | $32.00 Million | -0.31% |
| 2021-12-31 | $32.10 Million | -3.78% |
| 2020-12-31 | $33.36 Million | -3.31% |
| 2019-12-31 | $34.51 Million | -77.34% |
| 2018-12-31 | $152.29 Million | +277.71% |
| 2017-12-31 | $40.32 Million | -37.79% |
| 2016-12-31 | $64.81 Million | +113.69% |
| 2015-12-31 | $30.33 Million | +156.11% |
| 2014-12-31 | $11.84 Million | +59.12% |
| 2013-12-31 | $7.44 Million | +43.69% |
| 2012-12-31 | $5.18 Million | +2.02% |
| 2011-12-31 | $5.08 Million | +181.82% |
| 2010-12-31 | $1.80 Million | -23.46% |
| 2009-12-31 | $2.35 Million | -50.07% |
| 2008-12-31 | $4.71 Million | +34.41% |
| 2007-12-31 | $3.51 Million | -89.32% |
| 2006-12-31 | $32.84 Million | +4.42% |
| 2005-12-31 | $31.45 Million | +2481.29% |
| 2004-12-31 | $1.22 Million | +647.29% |
| 2003-12-31 | $163.04K | -83.41% |
| 2002-12-31 | $983.08K | +7.26% |
| 2001-12-31 | $916.49K | +241.25% |
| 2000-12-31 | $268.57K | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, P… Read more